Trials / Unknown
UnknownNCT01953055
SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)
Phase II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Sunnybrook Health Sciences Centre · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Current treatment options for high risk localized prostate cancer include radical prostatectomy +/- postoperative radiotherapy, radical radiotherapy with androgen deprivation therapy. Evidence has emerged that prostate cancer has a low α/β ratio in the range of 1-3 Gy. Even with high risk tumors, prostate cancer is hypothesized to have a greater sensitivity to large fraction sizes and high dose per fraction radiotherapy theoretically allows for biological dose escalation with fewer visits and no additional toxicity. Therefore, we hope to determine the toxicity, quality of life, biochemical and pathological control of SBRT for high risk prostate cancer incorporating ENI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Stereotactic ablative radiotherapy |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2019-09-01
- Completion
- 2023-09-01
- First posted
- 2013-09-30
- Last updated
- 2020-11-24
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01953055. Inclusion in this directory is not an endorsement.